 |
Market Research Report
Hepatitis B - Pipeline Review, H1 2018 |
||||||
| Published by | Global Markets Direct | Product code | 232823 | ||||
| Published | Content info | 365 Pages Delivery time: 1-2 business days |
|||||
| Price |
|
||||||
| Hepatitis B - Pipeline Review, H1 2018 | ||
| Published: May 16, 2018 | Content info: 365 Pages |
|
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H1 2018, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 9, 26, 24, 1, 69, 29 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 9 and 3 molecules, respectively.
Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
